Search Results - "Hughan, K. S."

  • Showing 1 - 3 results of 3
Refine Results
  1. 1
    Pharmacokinetic and pharmacodynamic profile of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial

    Pharmacokinetic and pharmacodynamic profile of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial by Laffel, L. M. B., Tamborlane, W. V., Yver, A., Simons, G., Wu, J., Nock, V., Hobson, D., Hughan, K. S., Kaspers, S., Marquard, J.

    Published in Diabetic medicine (01-08-2018)
    “…Aims To assess the pharmacokinetic and pharmacodynamic profile of a single dose of empagliflozin in young people with Type 2 diabetes to identify the…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  2. 2
    Men's health in the modern era of cystic fibrosis

    Men's health in the modern era of cystic fibrosis by Khan, F.N., Tangpricha, V., Hughan, K.S., Jain, R., Ladores, S.L., Taylor-Cousar, J.L., West, N.E., Montemayor, K., Sawicki, G.S., Uluer, A., Aitken, M.L., Shnorhavorian, M., Bray, L.A., Kvam, C., Stalvey, M., Kazmerski, T.M.

    Published in Journal of cystic fibrosis (01-11-2021)
    Get full text
    Journal Article
    Save to List
    Saved in:
  3. 3
    C96 SUGARS AND FATS- ENERGY UTILIZATION IN PULMONARY HYPERTENSION: Sirt3-Ampk Activation By Nitrite And Metformin Improves Hyperglycemia And Normalizes Pulmonary Hypertension In Heart Failure With Preserved Ejection Fraction (ph-Hfpef)

    C96 SUGARS AND FATS- ENERGY UTILIZATION IN PULMONARY HYPERTENSION: Sirt3-Ampk Activation By Nitrite And Metformin Improves Hyperglycemia And Normalizes Pulmonary Hypertension In Heart Failure With Preserved Ejection Fraction (ph-Hfpef) by Lai, Y, Tabima, D M, Dube, J J, Hughan, K S, Goncharov, D, Vanderpool, R R, Goncharova, E A, Tofovic, S P, Mora, A L, Gladwin, M T

    Get full text
    Journal Article
    Save to List
    Saved in:

Search Tools: